CRC Research Update — July 15, 2026
Today's colorectal cancer research highlights
crc-research
A collection of 723 issues
CRC Research Finding
Skip to content
The CRC Digest
♥ Phone-Based Patient Navigation Tested to Improve Genetic Testing Access
A pilot randomized trial in an academic health system evaluated whether offering newly diagnosed CRC patients free, phone-based patient navigation increased rates of referral, counseling, and germline genetic testing compared to usual care. The study
CRC Research Update — July 14, 2026
Today's colorectal cancer research highlights
CRC Research Finding
Skip to content
The CRC Digest
▸ Meta-Analysis Confirms Targeted Therapy Benefits for Colorectal Cancer Liver Metastases
A systematic review and meta-analysis evaluated targeted therapy in colorectal cancer liver metastases, examining overall survival, progression-free survival, objective response rate, and conversion to resection. The analysis provides comprehensive evidence on the role of
CRC Research Update — July 13, 2026
Today's colorectal cancer research highlights
New Hawaii Law Expands Coverage for Colorectal Cancer Screenings
Skip to content
The CRC Digest
New Hawaii Law Expands Coverage for Colorectal Cancer Screenings
Hawaii enacts new law expanding coverage for colorectal cancer screenings. (Hawaii News Now)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest
Liquid Biopsy Platform Now Detects Early-Stage Disease
Skip to content
The CRC Digest
Liquid Biopsy Platform Now Detects Early-Stage Disease
Plasmonic technology expanded to early-stage colorectal cancer. (EurekAlert)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
Furin Inhibition Targets KRAS and BRAF Pathways
Skip to content
The CRC Digest
Furin Inhibition Targets KRAS and BRAF Pathways
Blocking Furin improved chemotherapy sensitivity in KRAS- and BRAF-mutant organoids. (Oncogene)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
Jemperli Shows Sustained Response in dMMR/MSI-H Rectal Cancer
Skip to content
The CRC Digest
Jemperli Shows Sustained Response in dMMR/MSI-H Rectal Cancer
Phase 2 data support potential organ preservation in patients with mismatch repair deficient tumors. (Fierce Pharma)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026
CRC Research Finding
Skip to content
The CRC Digest
◇ Furin Protein Sustains Tumor Signals in KRAS- and BRAF-Mutated Colorectal Cancer
Preclinical research identifies Furin as a key mediator of the TGF-β1-COX-2 pathway in KRAS- and BRAF-mutant colorectal cancer; blocking Furin suppressed tumor growth and enhanced sensitivity to chemotherapy in organoid models. (Oncogene)
This